Trial Profile

EpCAM-targeted chimeric antigen receptor modified autologous T cells for clinical research of advanced gastric cancer

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 05 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Danburstotug (Primary)
Indications Gastric cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
04 Jun 2024 New trial record
01 Jun 2024 According to an Immunofoco Biotech media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting scheduled from May 31 to June 4, 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com